HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused o...

Related Keywords

Boston ,Massachusetts ,United States ,Kanghua ,Guangdong ,China ,Sichuan ,Gansu ,Chengdu ,Shane Maltbie ,Rob Hershberg ,Wennian Wu ,Wang Zhentao ,Postdoctoral Innovation Practice ,National Medical Products Administration ,Group Ltd ,Nasdaq ,Chengdu Kanghua Biological Products Co Ltd ,Takeda Vaccines Inc ,Hillevax Inc ,Ministry Of Science ,Ministry Of Personnel ,Exchange Commission ,Investigational New Drug ,Chief Executive Officer ,Human Rabies Vaccine ,Human Diploid Cells ,Kanghua Biological ,Innovation Practice ,Enterprise Cultivation ,Honest Demonstration Unit ,Sichuan Province ,National Medical Products ,Takeda Vaccines ,Private Securities Litigation Reform Act ,Vax Contact ,